NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

iclight,

I’d be careful about who you calm brain challenged; ). What you conveniently provide is the rGBM patients who generally have about an 85% likelihood of having mesenchymal phenotype GBM which offers many more neoantigen targets. The best long term survival starts with early treatment but there is great interim benefit for those who had rGBM and crossed over. So much so that even those who likely evented early on SOC were more than covered by the benefit the rest received. Notice how the two lines you address converge?; ). I think you missed that part of the data interpretation. Best wishes